Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 78

1.

Efficacy of Human Monoclonal Antibody Monotherapy Against Bundibugyo Virus Infection in Nonhuman Primates.

Gilchuk P, Mire CE, Geisbert JB, Agans KN, Deer DJ, Cross RW, Slaughter JC, Flyak AI, Mani J, Pauly MH, Velasco J, Whaley KJ, Zeitlin L, Geisbert TW, Crowe JE Jr.

J Infect Dis. 2018 Jul 5. doi: 10.1093/infdis/jiy295. [Epub ahead of print]

PMID:
29982718
2.

Postexposure Efficacy of Recombinant Vesicular Stomatitis Virus Vectors Against High and Low Doses of Marburg Virus Variant Angola in Nonhuman Primates.

Woolsey C, Geisbert JB, Matassov D, Agans KN, Borisevich V, Cross RW, Deer DJ, Fenton KA, Eldridge JH, Mire CE, Geisbert TW.

J Infect Dis. 2018 Jun 25. doi: 10.1093/infdis/jiy293. [Epub ahead of print]

PMID:
29939296
3.

Single Dose Trivalent Vesiculovax Vaccine Protects Macaques from Lethal Ebolavirus and Marburgvirus Challenge.

Matassov D, Mire CE, Latham T, Geisbert JB, Xu R, Ota-Setlik A, Agans KN, Kobs DJ, Wendling MQS, Burnaugh A, Rudge TL Jr, Sabourin CL, Egan MA, Clarke DK, Geisbert TW, Eldridge JH.

J Virol. 2017 Nov 15. pii: JVI.01190-17. doi: 10.1128/JVI.01190-17. [Epub ahead of print]

4.

Transcriptome Analysis of Circulating Immune Cell Subsets Highlight the Role of Monocytes in Zaire Ebola Virus Makona Pathogenesis.

Menicucci AR, Versteeg K, Woolsey C, Mire CE, Geisbert JB, Cross RW, Agans KN, Jankeel A, Geisbert TW, Messaoudi I.

Front Immunol. 2017 Oct 26;8:1372. doi: 10.3389/fimmu.2017.01372. eCollection 2017.

5.

siRNA rescues nonhuman primates from advanced Marburg and Ravn virus disease.

Thi EP, Mire CE, Lee AC, Geisbert JB, Ursic-Bedoya R, Agans KN, Robbins M, Deer DJ, Cross RW, Kondratowicz AS, Fenton KA, MacLachlan I, Geisbert TW.

J Clin Invest. 2017 Dec 1;127(12):4437-4448. doi: 10.1172/JCI96185. Epub 2017 Nov 6.

6.

Human-monoclonal-antibody therapy protects nonhuman primates against advanced Lassa fever.

Mire CE, Cross RW, Geisbert JB, Borisevich V, Agans KN, Deer DJ, Heinrich ML, Rowland MM, Goba A, Momoh M, Boisen ML, Grant DS, Fullah M, Khan SH, Fenton KA, Robinson JE, Branco LM, Garry RF, Geisbert TW.

Nat Med. 2017 Oct;23(10):1146-1149. doi: 10.1038/nm.4396. Epub 2017 Sep 4.

7.

Infection with the Makona variant results in a delayed and distinct host immune response compared to previous Ebola virus variants.

Versteeg K, Menicucci AR, Woolsey C, Mire CE, Geisbert JB, Cross RW, Agans KN, Jeske D, Messaoudi I, Geisbert TW.

Sci Rep. 2017 Aug 29;7(1):9730. doi: 10.1038/s41598-017-09963-y.

8.

Therapeutic treatment of Marburg and Ravn virus infection in nonhuman primates with a human monoclonal antibody.

Mire CE, Geisbert JB, Borisevich V, Fenton KA, Agans KN, Flyak AI, Deer DJ, Steinkellner H, Bohorov O, Bohorova N, Goodman C, Hiatt A, Kim DH, Pauly MH, Velasco J, Whaley KJ, Crowe JE Jr, Zeitlin L, Geisbert TW.

Sci Transl Med. 2017 Apr 5;9(384). pii: eaai8711. doi: 10.1126/scitranslmed.aai8711.

9.

Assessment of the potential for host-targeted iminosugars UV-4 and UV-5 activity against filovirus infections in vitro and in vivo.

Warfield KL, Warren TK, Qiu X, Wells J, Mire CE, Geisbert JB, Stuthman KS, Garza NL, Van Tongeren SA, Shurtleff AC, Agans KN, Wong G, Callahan MV, Geisbert TW, Klose B, Ramstedt U, Treston AM.

Antiviral Res. 2017 Feb;138:22-31. doi: 10.1016/j.antiviral.2016.11.019. Epub 2016 Nov 28.

PMID:
27908828
10.

Rescue of non-human primates from advanced Sudan ebolavirus infection with lipid encapsulated siRNA.

Thi EP, Lee AC, Geisbert JB, Ursic-Bedoya R, Agans KN, Robbins M, Deer DJ, Fenton KA, Kondratowicz AS, MacLachlan I, Geisbert TW, Mire CE.

Nat Microbiol. 2016 Aug 22;1(10):16142. doi: 10.1038/nmicrobiol.2016.142.

11.

Analytical Validation of the ReEBOV Antigen Rapid Test for Point-of-Care Diagnosis of Ebola Virus Infection.

Cross RW, Boisen ML, Millett MM, Nelson DS, Oottamasathien D, Hartnett JN, Jones AB, Goba A, Momoh M, Fullah M, Bornholdt ZA, Fusco ML, Abelson DM, Oda S, Brown BL, Pham H, Rowland MM, Agans KN, Geisbert JB, Heinrich ML, Kulakosky PC, Shaffer JG, Schieffelin JS, Kargbo B, Gbetuwa M, Gevao SM, Wilson RB, Saphire EO, Pitts KR, Khan SH, Grant DS, Geisbert TW, Branco LM, Garry RF.

J Infect Dis. 2016 Oct 15;214(suppl 3):S210-S217. Epub 2016 Aug 31.

12.

Passive Immunotherapy: Assessment of Convalescent Serum Against Ebola Virus Makona Infection in Nonhuman Primates.

Mire CE, Geisbert JB, Agans KN, Thi EP, Lee AC, Fenton KA, Geisbert TW.

J Infect Dis. 2016 Oct 15;214(suppl 3):S367-S374. Epub 2016 Aug 28.

13.

Treatment of Lassa virus infection in outbred guinea pigs with first-in-class human monoclonal antibodies.

Cross RW, Mire CE, Branco LM, Geisbert JB, Rowland MM, Heinrich ML, Goba A, Momoh M, Grant DS, Fullah M, Khan SH, Robinson JE, Geisbert TW, Garry RF.

Antiviral Res. 2016 Sep;133:218-222. doi: 10.1016/j.antiviral.2016.08.012. Epub 2016 Aug 13.

14.

Field Validation of the ReEBOV Antigen Rapid Test for Point-of-Care Diagnosis of Ebola Virus Infection.

Boisen ML, Cross RW, Hartnett JN, Goba A, Momoh M, Fullah M, Gbakie M, Safa S, Fonnie M, Baimba F, Koroma VJ, Geisbert JB, McCormick S, Nelson DK, Millett MM, Oottamasathien D, Jones AB, Pham H, Brown BL, Shaffer JG, Schieffelin JS, Kargbo B, Gbetuwa M, Gevao SM, Wilson RB, Pitts KR, Geisbert TW, Branco LM, Khan SH, Grant DS, Garry RF.

J Infect Dis. 2016 Oct 15;214(suppl 3):S203-S209. Epub 2016 Aug 11.

15.

Pathogenic Differences between Nipah Virus Bangladesh and Malaysia Strains in Primates: Implications for Antibody Therapy.

Mire CE, Satterfield BA, Geisbert JB, Agans KN, Borisevich V, Yan L, Chan YP, Cross RW, Fenton KA, Broder CC, Geisbert TW.

Sci Rep. 2016 Aug 3;6:30916. doi: 10.1038/srep30916.

16.

An Outbreak of Ebola Virus Disease in the Lassa Fever Zone.

Goba A, Khan SH, Fonnie M, Fullah M, Moigboi A, Kovoma A, Sinnah V, Yoko N, Rogers H, Safai S, Momoh M, Koroma V, Kamara FK, Konowu E, Yillah M, French I, Mustapha I, Kanneh F, Foday M, McCarthy H, Kallon T, Kallon M, Naiebu J, Sellu J, Jalloh AA, Gbakie M, Kanneh L, Massaly JL, Kargbo D, Kargbo B, Vandi M, Gbetuwa M, Gevao SM, Sandi JD, Jalloh SC, Grant DS, Blyden SO, Crozier I, Schieffelin JS, McLellan SL, Jacob ST, Boisen ML, Hartnett JN, Cross RW, Branco LM, Andersen KG, Yozwiak NL, Gire SK, Tariyal R, Park DJ, Haislip AM, Bishop CM, Melnik LI, Gallaher WR, Wimley WC, He J, Shaffer JG, Sullivan BM, Grillo S, Oman S, Garry CE, Edwards DR, McCormick SJ, Elliott DH, Rouelle JA, Kannadka CB, Reyna AA, Bradley BT, Yu H, Yenni RE, Hastie KM, Geisbert JB, Kulakosky PC, Wilson RB, Oldstone MB, Pitts KR, Henderson LA, Robinson JE, Geisbert TW, Saphire EO, Happi CT, Asogun DA, Sabeti PC, Garry RF; Viral Hemorrhagic Fever Consortium.

J Infect Dis. 2016 Oct 15;214(suppl 3):S110-S121. Epub 2016 Jul 11.

17.

The Domestic Ferret (Mustela putorius furo) as a Lethal Infection Model for 3 Species of Ebolavirus.

Cross RW, Mire CE, Borisevich V, Geisbert JB, Fenton KA, Geisbert TW.

J Infect Dis. 2016 Aug 15;214(4):565-9. doi: 10.1093/infdis/jiw209. Epub 2016 May 24.

18.

Oral and Conjunctival Exposure of Nonhuman Primates to Low Doses of Ebola Makona Virus.

Mire CE, Geisbert JB, Agans KN, Deer DJ, Fenton KA, Geisbert TW.

J Infect Dis. 2016 Oct 15;214(suppl 3):S263-S267. Epub 2016 Jun 9.

19.

Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits.

Robinson JE, Hastie KM, Cross RW, Yenni RE, Elliott DH, Rouelle JA, Kannadka CB, Smira AA, Garry CE, Bradley BT, Yu H, Shaffer JG, Boisen ML, Hartnett JN, Zandonatti MA, Rowland MM, Heinrich ML, Martínez-Sobrido L, Cheng B, de la Torre JC, Andersen KG, Goba A, Momoh M, Fullah M, Gbakie M, Kanneh L, Koroma VJ, Fonnie R, Jalloh SC, Kargbo B, Vandi MA, Gbetuwa M, Ikponmwosa O, Asogun DA, Okokhere PO, Follarin OA, Schieffelin JS, Pitts KR, Geisbert JB, Kulakoski PC, Wilson RB, Happi CT, Sabeti PC, Gevao SM, Khan SH, Grant DS, Geisbert TW, Saphire EO, Branco LM, Garry RF.

Nat Commun. 2016 May 10;7:11544. doi: 10.1038/ncomms11544.

20.

Monoclonal antibody therapy for Junin virus infection.

Zeitlin L, Geisbert JB, Deer DJ, Fenton KA, Bohorov O, Bohorova N, Goodman C, Kim D, Hiatt A, Pauly MH, Velasco J, Whaley KJ, Altmann F, Gruber C, Steinkellner H, Honko AN, Kuehne AI, Aman MJ, Sahandi S, Enterlein S, Zhan X, Enria D, Geisbert TW.

Proc Natl Acad Sci U S A. 2016 Apr 19;113(16):4458-63. doi: 10.1073/pnas.1600996113. Epub 2016 Apr 4.

21.

Development of Prototype Filovirus Recombinant Antigen Immunoassays.

Boisen ML, Oottamasathien D, Jones AB, Millett MM, Nelson DS, Bornholdt ZA, Fusco ML, Abelson DM, Oda S, Hartnett JN, Rowland MM, Heinrich ML, Akdag M, Goba A, Momoh M, Fullah M, Baimba F, Gbakie M, Safa S, Fonnie R, Kanneh L, Cross RW, Geisbert JB, Geisbert TW, Kulakosky PC, Grant DS, Shaffer JG, Schieffelin JS, Wilson RB, Saphire EO, Branco LM, Garry RF, Khan SH, Pitts KR; Viral Hemorrhagic Fever Consortium.

J Infect Dis. 2015 Oct 1;212 Suppl 2:S359-67. doi: 10.1093/infdis/jiv353. Epub 2015 Jul 30.

22.

Vaccination With a Highly Attenuated Recombinant Vesicular Stomatitis Virus Vector Protects Against Challenge With a Lethal Dose of Ebola Virus.

Matassov D, Marzi A, Latham T, Xu R, Ota-Setlik A, Feldmann F, Geisbert JB, Mire CE, Hamm S, Nowak B, Egan MA, Geisbert TW, Eldridge JH, Feldmann H, Clarke DK.

J Infect Dis. 2015 Oct 1;212 Suppl 2:S443-51. doi: 10.1093/infdis/jiv316. Epub 2015 Jun 24.

23.

Comparison of the Pathogenesis of the Angola and Ravn Strains of Marburg Virus in the Outbred Guinea Pig Model.

Cross RW, Fenton KA, Geisbert JB, Ebihara H, Mire CE, Geisbert TW.

J Infect Dis. 2015 Oct 1;212 Suppl 2:S258-70. doi: 10.1093/infdis/jiv182. Epub 2015 Jun 19.

24.

Modeling the Disease Course of Zaire ebolavirus Infection in the Outbred Guinea Pig.

Cross RW, Fenton KA, Geisbert JB, Mire CE, Geisbert TW.

J Infect Dis. 2015 Oct 1;212 Suppl 2:S305-15. doi: 10.1093/infdis/jiv237. Epub 2015 Jun 2.

PMID:
26038397
25.

A Single-Vector, Single-Injection Trivalent Filovirus Vaccine: Proof of Concept Study in Outbred Guinea Pigs.

Mire CE, Geisbert JB, Versteeg KM, Mamaeva N, Agans KN, Geisbert TW, Connor JH.

J Infect Dis. 2015 Oct 1;212 Suppl 2:S384-8. doi: 10.1093/infdis/jiv126. Epub 2015 May 9.

26.

Lipid nanoparticle siRNA treatment of Ebola-virus-Makona-infected nonhuman primates.

Thi EP, Mire CE, Lee AC, Geisbert JB, Zhou JZ, Agans KN, Snead NM, Deer DJ, Barnard TR, Fenton KA, MacLachlan I, Geisbert TW.

Nature. 2015 May 21;521(7552):362-5. doi: 10.1038/nature14442. Epub 2015 Apr 22.

27.

Single-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus.

Mire CE, Matassov D, Geisbert JB, Latham TE, Agans KN, Xu R, Ota-Setlik A, Egan MA, Fenton KA, Clarke DK, Eldridge JH, Geisbert TW.

Nature. 2015 Apr 30;520(7549):688-691. doi: 10.1038/nature14428. Epub 2015 Apr 8.

28.

Multiple circulating infections can mimic the early stages of viral hemorrhagic fevers and possible human exposure to filoviruses in Sierra Leone prior to the 2014 outbreak.

Boisen ML, Schieffelin JS, Goba A, Oottamasathien D, Jones AB, Shaffer JG, Hastie KM, Hartnett JN, Momoh M, Fullah M, Gabiki M, Safa S, Zandonatti M, Fusco M, Bornholdt Z, Abelson D, Gire SK, Andersen KG, Tariyal R, Stremlau M, Cross RW, Geisbert JB, Pitts KR, Geisbert TW, Kulakoski P, Wilson RB, Henderson L, Sabeti PC, Grant DS, Garry RF, Saphire EO, Branco LM, Khan SH; Viral Hemorrhagic Fever Consortium.

Viral Immunol. 2015 Feb;28(1):19-31. doi: 10.1089/vim.2014.0108.

29.

Marburg virus infection in nonhuman primates: Therapeutic treatment by lipid-encapsulated siRNA.

Thi EP, Mire CE, Ursic-Bedoya R, Geisbert JB, Lee ACH, Agans KN, Robbins M, Deer DJ, Fenton KA, MacLachlan I, Geisbert TW.

Sci Transl Med. 2014 Aug 20;6(250):250ra116. doi: 10.1126/scitranslmed.3009706.

30.

Transcriptional correlates of disease outcome in anticoagulant-treated non-human primates infected with ebolavirus.

Garamszegi S, Yen JY, Honko AN, Geisbert JB, Rubins KH, Geisbert TW, Xia Y, Hensley LE, Connor JH.

PLoS Negl Trop Dis. 2014 Jul 31;8(7):e3061. doi: 10.1371/journal.pntd.0003061. eCollection 2014.

31.

Therapeutic treatment of Nipah virus infection in nonhuman primates with a neutralizing human monoclonal antibody.

Geisbert TW, Mire CE, Geisbert JB, Chan YP, Agans KN, Feldmann F, Fenton KA, Zhu Z, Dimitrov DS, Scott DP, Bossart KN, Feldmann H, Broder CC.

Sci Transl Med. 2014 Jun 25;6(242):242ra82. doi: 10.1126/scitranslmed.3008929.

32.

Durability of a vesicular stomatitis virus-based marburg virus vaccine in nonhuman primates.

Mire CE, Geisbert JB, Agans KN, Satterfield BA, Versteeg KM, Fritz EA, Feldmann H, Hensley LE, Geisbert TW.

PLoS One. 2014 Apr 23;9(4):e94355. doi: 10.1371/journal.pone.0094355. eCollection 2014.

33.

Lassa fever in post-conflict sierra leone.

Shaffer JG, Grant DS, Schieffelin JS, Boisen ML, Goba A, Hartnett JN, Levy DC, Yenni RE, Moses LM, Fullah M, Momoh M, Fonnie M, Fonnie R, Kanneh L, Koroma VJ, Kargbo K, Ottomassathien D, Muncy IJ, Jones AB, Illick MM, Kulakosky PC, Haislip AM, Bishop CM, Elliot DH, Brown BL, Zhu H, Hastie KM, Andersen KG, Gire SK, Tabrizi S, Tariyal R, Stremlau M, Matschiner A, Sampey DB, Spence JS, Cross RW, Geisbert JB, Folarin OA, Happi CT, Pitts KR, Geske FJ, Geisbert TW, Saphire EO, Robinson JE, Wilson RB, Sabeti PC, Henderson LA, Khan SH, Bausch DG, Branco LM, Garry RF; Viral Hemorrhagic Fever Consortium.

PLoS Negl Trop Dis. 2014 Mar 20;8(3):e2748. doi: 10.1371/journal.pntd.0002748. eCollection 2014 Mar.

34.

A recombinant Hendra virus G glycoprotein subunit vaccine protects nonhuman primates against Hendra virus challenge.

Mire CE, Geisbert JB, Agans KN, Feng YR, Fenton KA, Bossart KN, Yan L, Chan YP, Broder CC, Geisbert TW.

J Virol. 2014 May;88(9):4624-31. doi: 10.1128/JVI.00005-14. Epub 2014 Feb 12.

35.

Vesicular stomatitis virus-based vaccines protect nonhuman primates against Bundibugyo ebolavirus.

Mire CE, Geisbert JB, Marzi A, Agans KN, Feldmann H, Geisbert TW.

PLoS Negl Trop Dis. 2013 Dec 19;7(12):e2600. doi: 10.1371/journal.pntd.0002600. eCollection 2013.

36.

Protection against lethal Marburg virus infection mediated by lipid encapsulated small interfering RNA.

Ursic-Bedoya R, Mire CE, Robbins M, Geisbert JB, Judge A, MacLachlan I, Geisbert TW.

J Infect Dis. 2014 Feb 15;209(4):562-70. doi: 10.1093/infdis/jit465. Epub 2013 Aug 29.

37.

A Hendra virus G glycoprotein subunit vaccine protects African green monkeys from Nipah virus challenge.

Bossart KN, Rockx B, Feldmann F, Brining D, Scott D, LaCasse R, Geisbert JB, Feng YR, Chan YP, Hickey AC, Broder CC, Feldmann H, Geisbert TW.

Sci Transl Med. 2012 Aug 8;4(146):146ra107. doi: 10.1126/scitranslmed.3004241.

38.

Recombinant vesicular stomatitis virus vaccine vectors expressing filovirus glycoproteins lack neurovirulence in nonhuman primates.

Mire CE, Miller AD, Carville A, Westmoreland SV, Geisbert JB, Mansfield KG, Feldmann H, Hensley LE, Geisbert TW.

PLoS Negl Trop Dis. 2012;6(3):e1567. doi: 10.1371/journal.pntd.0001567. Epub 2012 Mar 20.

39.

A neutralizing human monoclonal antibody protects african green monkeys from hendra virus challenge.

Bossart KN, Geisbert TW, Feldmann H, Zhu Z, Feldmann F, Geisbert JB, Yan L, Feng YR, Brining D, Scott D, Wang Y, Dimitrov AS, Callison J, Chan YP, Hickey AC, Dimitrov DS, Broder CC, Rockx B.

Sci Transl Med. 2011 Oct 19;3(105):105ra103. doi: 10.1126/scitranslmed.3002901.

40.

Therapeutics of Ebola hemorrhagic fever: whole-genome transcriptional analysis of successful disease mitigation.

Yen JY, Garamszegi S, Geisbert JB, Rubins KH, Geisbert TW, Honko A, Xia Y, Connor JH, Hensley LE.

J Infect Dis. 2011 Nov;204 Suppl 3:S1043-52. doi: 10.1093/infdis/jir345.

PMID:
21987740
41.

Pathogenesis of Marburg hemorrhagic fever in cynomolgus macaques.

Hensley LE, Alves DA, Geisbert JB, Fritz EA, Reed C, Larsen T, Geisbert TW.

J Infect Dis. 2011 Nov;204 Suppl 3:S1021-31. doi: 10.1093/infdis/jir339.

PMID:
21987738
42.

CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates.

Sullivan NJ, Hensley L, Asiedu C, Geisbert TW, Stanley D, Johnson J, Honko A, Olinger G, Bailey M, Geisbert JB, Reimann KA, Bao S, Rao S, Roederer M, Jahrling PB, Koup RA, Nabel GJ.

Nat Med. 2011 Aug 21;17(9):1128-31. doi: 10.1038/nm.2447.

PMID:
21857654
43.

Pathogenesis of Lassa fever in cynomolgus macaques.

Hensley LE, Smith MA, Geisbert JB, Fritz EA, Daddario-DiCaprio KM, Larsen T, Geisbert TW.

Virol J. 2011 May 6;8:205. doi: 10.1186/1743-422X-8-205.

44.

A novel model of lethal Hendra virus infection in African green monkeys and the effectiveness of ribavirin treatment.

Rockx B, Bossart KN, Feldmann F, Geisbert JB, Hickey AC, Brining D, Callison J, Safronetz D, Marzi A, Kercher L, Long D, Broder CC, Feldmann H, Geisbert TW.

J Virol. 2010 Oct;84(19):9831-9. doi: 10.1128/JVI.01163-10. Epub 2010 Jul 21.

45.

Vector choice determines immunogenicity and potency of genetic vaccines against Angola Marburg virus in nonhuman primates.

Geisbert TW, Bailey M, Geisbert JB, Asiedu C, Roederer M, Grazia-Pau M, Custers J, Jahrling P, Goudsmit J, Koup R, Sullivan NJ.

J Virol. 2010 Oct;84(19):10386-94. doi: 10.1128/JVI.00594-10. Epub 2010 Jul 21.

46.

Postexposure treatment of Marburg virus infection.

Geisbert TW, Hensley LE, Geisbert JB, Leung A, Johnson JC, Grolla A, Feldmann H.

Emerg Infect Dis. 2010 Jul;16(7):1119-22. doi: 10.3201/eid1607.100159.

47.

Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study.

Geisbert TW, Lee AC, Robbins M, Geisbert JB, Honko AN, Sood V, Johnson JC, de Jong S, Tavakoli I, Judge A, Hensley LE, Maclachlan I.

Lancet. 2010 May 29;375(9729):1896-905. doi: 10.1016/S0140-6736(10)60357-1.

PMID:
20511019
48.

Development of an acute and highly pathogenic nonhuman primate model of Nipah virus infection.

Geisbert TW, Daddario-DiCaprio KM, Hickey AC, Smith MA, Chan YP, Wang LF, Mattapallil JJ, Geisbert JB, Bossart KN, Broder CC.

PLoS One. 2010 May 18;5(5):e10690. doi: 10.1371/journal.pone.0010690.

49.

Potential impact of a 2-person security rule on BioSafety Level 4 laboratory workers.

LeDuc JW, Anderson K, Bloom ME, Carrion R Jr, Feldmann H, Fitch JP, Geisbert JB, Geisbert TW, Holbrook MR, Jahrling PB, Ksiazek TG.

Emerg Infect Dis. 2009 Jul;15(7):e1. doi: 10.3201/eid1507.081523.

50.

Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus.

Geisbert TW, Geisbert JB, Leung A, Daddario-DiCaprio KM, Hensley LE, Grolla A, Feldmann H.

J Virol. 2009 Jul;83(14):7296-304. doi: 10.1128/JVI.00561-09. Epub 2009 Apr 22.

Supplemental Content

Loading ...
Support Center